Good morning, everyone, and welcome to another working week, although this will be an abbreviated session on this side of the pond, thanks to a looming holiday. Nonetheless, the world keeps spinning, so we are undertaking our usual routine of meetings, deadlines, and due diligence in our quest to provide interesting items for your journey. On that note, time to get cracking. So please join us as we fire up the coffee kettle and dig in. Hope your day is smashing and, as always, please do keep in touch …

Astra Zeneca (AZN) has begun succession planning for Pascal Soriot, its chief executive of six years, after pressure from shareholders, the Times of London reports. The drug maker, which suffered the failure of a big lung cancer trial last week, has engaged headhunters to assess internal candidates. However, Soriot is not expected to leave imminently, despite rumors last year linking him to Teva Pharmaceutical, but shareholders have warned the company needs to prepare. Recently, Soriot said he has “no plans to move on.”

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy